A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT01691846

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01691846
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01691846. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2013-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
aleglitazar+metformin
Intervention (Drug)
placebo+metformin
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct01691846
Content hash
5f98403db1238e4191c9c7f95e646835b81af83850c4e0551e3c9b4a301b6493